Solid Bioscience planned its IPO for months, but waited until the day before its market debut on Friday, Jan. 26, to tell investors about an FDA hold on its key drug candidate.
Burlington, Mass.-based Flexion Therapeutics said Friday it has receive FDA approval for osteoarthritis knee pain treatment Zilretta, a non-opioid medicine utilizing Flexion's microsphere technology.
Jim Cramer says some sellers are making a big mistake by not giving top-notch CEOs the benefit of the doubt despite earnings upheaval.
Jim Cramer is bullish on Hertz Global Holdings, Honeywell, PetMed Express, and Allergan.
Albany Molecular Research, Acorda Therapeutics and PTC Therapeutics were among the biotech stock movers in premarket trading on Tuesday.